Following the FDA approval of lirafugratinib (Lyrfigtu) for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma, there are currently 3 FGFR2 inhibi ...
“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.
Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.
In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.
In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA ...
Ethan B. Ludmir, MD, explains why advanced radiation techniques like protons fit nonoperative cholangiocarcinoma better than ...
In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in ...
Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.
The faculty then trace the development history of belantamab mafodotin. They describe the landscape around 2018, when daratumumab as a single agent produced a response rate close to 30% and only naked ...
The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.
Ayal Aizer, MD, MHS, says Alliance A071801 supports fractionated SRS as standard after resection, with comparable radiation necrosis rates. In an interview with CancerNetwork®, Ayal Aizer, MD, MHS, ...
The 10-year results from the phase 3 CHN HYPOPMRT trial (NCT00793962) showed that hypofractionated postmastectomy radiotherapy (PMRT) delivered over 3 weeks maintained durable locoregional control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results